Can DPA act as a reservoir for long-chain omega-3s by converting to EPA and DHA?

Clinical evidence and metabolic dynamics

• Human dietary intervention studies and supplementation trials demonstrate that docosapentaenoic acid (DPA) effectively modulates long-chain omega-3 status by acting as a dynamic buffer. In clinical trials administering purified DPA, researchers observe a significant increase in eicosapentaenoic acid (EPA) levels within plasma and red blood cell phospholipids, confirming active retroconversion.
• Conversely, human supplementation trials show that dietary DPA does not lead to a proportional increase in circulating docosahexaenoic acid (DHA) levels. This suggests that while DPA readily buffers EPA, its capacity to elevate DHA levels under normal physiological conditions is minimal.

Mechanistic pathways

• Biochemically, DPA (22:5n-3) occupies a critical intermediary position in the omega-3 pathway. The retroconversion of DPA to EPA (20:5n-3) is mediated via peroxisomal $\beta$-oxidation, which serves as a rapid and efficient feedback loop to maintain EPA levels.
• The forward conversion of DPA to DHA (22:6n-3) involves a more complex, multi-step pathway. DPA must first be elongated to 24:5n-3 by elongase enzymes (specifically ELOVL2 and ELOVL5), desaturated by $\Delta$6-desaturase to 24:6n-3, and then translocated to peroxisomes for a single round of $\beta$-oxidation to produce DHA. This forward pathway is highly regulated and shares rate-limiting enzymes with other polyunsaturated fatty acid pathways, which limits the overall rate of DHA synthesis in vivo.

Bottom line

• DPA acts as a functional metabolic reservoir that actively retroconverts to EPA to buffer long-chain omega-3 status, but its forward conversion to DHA is tightly restricted in humans. The claim is partially supported, with DPA serving as a highly effective pool for EPA but not a primary source for DHA.